BioSpace News Archive

Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”) today announced that the Company will participate in the virtual KeyBanc Life Sciences & MedTech Investor Forum on March 19, 2024.

Scorpius Holdings, Inc., an integrated contract development and manufacturing organization, announced the closing of its previously announced public offering of 10,000,000 shares of its common stock at a public offering price of $0.15 per share, for gross proceeds of $1,500,000, before deducting underwriting discounts and offering expenses.

Intelligent Bio Solutions Inc. announced the closing of its previously announced private placement priced at-the-market under Nasdaq rules of 2,223,333 shares of common stock, Series H-1 warrants to purchase up to an aggregate of 2,223,333 shares of common stock and Series H-2 warrants to purchase up to an aggregate of 2,223,333 shares of common stock, at a combined purchase price of $4.55 per share of common stock and associated Series H-1 warrants and Series H-2 warrants.

InnoCare Pharma (HKEX: 09969; SSE: 688428) announced today the approval of the Investigational New Drug (IND) to conduct the clinical trial of B-cell lymphoma-2 (BCL2) inhibitor ICP-248 in combination with Bruton’s tyrosine kinase (BTK) inhibitor orelabrutinib as first-line therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in China.

The Leukemia & Lymphoma Society announced that BeiGene, Ltd., a global oncology company, has signed a three-year partnership to join LLS as the National Presenting Sponsor of Survivorship & Hope at Light The Night philanthropic events across the U.S. helping to support blood cancer patients and families who have emerged from the darkness of cancer.

Heart Test Laboratories, Inc. d/b/a HeartSciences, an artificial intelligence -powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, announced the publication, in Cardiovascular Diabetology, of an independent, peer-reviewed study utilizing its MyoVista® proprietary technology.

Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”) is excited to announce the highly anticipated release and availability of ‘PRIME’ by MangoRx, Powered by Kyzatrex®️ (“PRIME”) bringing the FDA-approved oral testosterone replacement therapy (TRT) treatment to consumers across the U.S via its proprietary telehealth platform.

Helius Medical Technologies, Inc. today announced the initiation of an open-label study for its registrational program in stroke.

Beckman Coulter Diagnostics, a clinical diagnostics leader, and Fujirebio, a leader in neurological markers and In Vitro Diagnostic manufacturing, announced an expansion of their partnership focused on development, manufacturing and clinical adoption of neurodegenerative disease assays.

Moleculin Biotech, Inc. today announced Jonathan Foster, Executive VP and Chief Financial Officer of Moleculin will participate in a fireside chat at the 36th Annual ROTH Conference on March 18, 2024 at 9:00 AM PT.